Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Down 14.2% in January

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 354,100 shares, a decrease of 14.2% from the December 31st total of 412,600 shares. Based on an average daily trading volume, of 301,300 shares, the days-to-cover ratio is presently 1.2 days.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SPRO shares. Evercore ISI lowered shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective on the stock. in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Spero Therapeutics in a report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th. Finally, TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Spero Therapeutics stock. Renaissance Technologies LLC raised its position in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 975,952 shares of the company’s stock after acquiring an additional 121,492 shares during the quarter. Renaissance Technologies LLC owned approximately 1.81% of Spero Therapeutics worth $1,269,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Trading Down 1.5 %

Shares of Spero Therapeutics stock traded down $0.01 during trading hours on Friday, reaching $0.86. 67,114 shares of the company’s stock were exchanged, compared to its average volume of 194,923. The company has a 50 day moving average of $1.01 and a two-hundred day moving average of $1.20. The stock has a market cap of $46.70 million, a P/E ratio of 12.24 and a beta of 0.63. Spero Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $1.89.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.